Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: A European Renal Best Practice (ERBP) commentary statement

Nephrology Dialysis Transplantation

Volumn 25, Issue 12, 2010, Pages 3823-3831

  Goldsmith, David J A ^a   Covic, Adrian ^b   Fouque, Denis ^c   Locatelli, Francesco ^d   Olgaard, Klaus ^e   Rodriguez, Mariano ^f   Spasovski, Goce ^g   Urena, Pablo ^h   Zoccali, Carmine ⁱ   London, Gérard Michel ^j   Vanholder, Raymond ^k  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^c UNIVERSITÉ LYON 1   (France)

^d A MANZONI HOSPITAL   (Italy)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^j PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

calcium; chronic kidney disease mineral and bone disorder; colecalciferol; phosphate; vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIDIOL 1 MONOOXYGENASE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; DEOXYPYRIDINOLINE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PROCOLLAGEN; PYRIDINOLINE; TELOPEPTIDE; VITAMIN D DERIVATIVE;

ABDOMINAL RADIOGRAPHY; ALUMINUM OVERLOAD; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DISEASE; BONE PAIN; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIAGNOSTIC IMAGING; DISEASE COURSE; ECHOCARDIOGRAPHY; FRACTURE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES CHRONIC KIDNEY DISEASE MINERAL AND BONE DISORDER GUIDELINE; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; VITAMIN D DEFICIENCY;

BONE DENSITY; BONE DISEASES; CALCIUM; CHRONIC DISEASE; COMORBIDITY; DISEASE PROGRESSION; EUROPE; HUMANS; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC;

EID: 78649498860     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq513     Document Type: Review

References (39)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; S1-S130
2. Moe S, Drüeke T, Cunningham J et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
3. Vanholder R, Abramowicz D, Jorge B et al. The future of European Nephrology 'Guidelines'-a declaration of intent by European Renal Best Practice (ERBP). NDT Plus 2009; 2: 213-221
4. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
5. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523
6. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
7. Tentori F. Trends in medication use and clinical outcomes in twelve countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Contrib Nephrol 2008; 161: 48-54
8. Hodsman A, Lamb EJ, Steenkamp R et al. UK Renal Registry 11th Annual Report (December 2008): Chapter 10. Biochemistry profile of patients receiving dialysis in the UK in 2007: national and centre-specific analyses. Nephron Clin Pract 2009; 111: c185-c225
9. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
10. Wald R, Tentori F, Tighiouart H et al. Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. Am J Kidney Dis 2007; 49: 257-266
11. Arenas MD, Alvarez-Ude F, Gil MT et al. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22: 1639-1644 (Pubitemid 47073763)
12. Manns BJ, Hodsman A, Zimmerman DL et al. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55: 800-812
13. Uhlig K, Berns JS, Kestenbaum B et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55: 773-799
14. Locatelli F, Covic A, Eckardt KU et al. ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354
15. Covic A, Abramowicz D, Bruchfeld A et al. ERA-EDTA ERBP Advisory Board. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant 2009; 24: 719-727
16. Tattersall J, Canaud B, Heimburger O et al. European Renal Best Practice Advisory Board. High-flux or low-flux dialysis: a position statement following publication of the Membrane Permeability Outcome Study. Nephrol Dial Transplant 2010; 25: 1230-1232
17. Matias PJ, Jorge C, Ferreira C et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905-911
18. Gal-Moscovici A, Sprague SM. Use of vitamin D in chronic kidney disease patients. Kidney Int 2010; 78: 146-151
19. Yin L, Grandi N, Raum E et al. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010; 46: 2196-2205
20. Biggar PH, Liangos O, Fey H et al. Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug? Pediatr Nephrol 2010; In press
21. Jorde R, Sneve M, Hutchinson M et al. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010; 171: 903-908
22. Covic A, Voroneanu L, Goldsmith D. The effects of vitamin D therapy on left ventricular structure and function-are these the underlying explanations for improved CKD patient survival? Nephron Clin Pract 2010; 116: c187-c195
23. Souberbielle JC, Cavalier E, Jean G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory? Clin Chem Lab Med 2010; 48: 769-774
24. Adragao T, Herberth J, Monier-Faugere MC et al. Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients. Osteoporos Int 2010; 21: 619-625
25. Moore C, YeeJ,Malluche H et al. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1484-1493
26. Goldsmith D. Routine screening for vascular calcification in chronic kidney disease-the case against. Semin Dial 2010; 23: 280-282
27. London GM. Awareness of vascular calcification alters mineral metabolism management. Semin Dial 2010; 23: 267-270
28. Block GA, Persky MS, Ketteler M et al. A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodial Int 2009; 13: 360-362
29. Drüeke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol 2009; 4: 234-241
30. Fouque D, Vennegoor M, ter Wee P et al. EBPG guideline on nutrition. Nephrol Dial Transplant 2007; 22: ii45-ii87
31. Kuhlmann MK. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 2010; 29: 137-144
32. Tonelli M, Wang W, Hemmelgarn B et al. Alberta Kidney Disease Network. Phosphate removal with several thrice-weekly dialysis methods in overweight hemodialysis patients. Am J Kidney Dis 2009; 54: 1108-1115
33. Ferreira A, Frazão JM, Monier-Faugere MC et al. Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412
34. Amerling R, Harbord NB, Pullman J et al. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 2010; 29: 293-299
35. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385-1393
36. Walsh SB, Altmann P, Pattison J et al. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis 2009; 53: 856-865
37. Spasovski G, Gelev S, Masin-Spasovska J et al. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone 2007; 41: 698-703 (Pubitemid 47385440)
38. Mahajan A, Narayanan M, Jaffers G et al. Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTH. Hemodial Int 2009; 13: 547-550
39. Zoccali C, Abramowicz D, Cannata-Andia JB et al. European Best Practice Guidelines; European Renal Best Practice. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant 2008; 23: 2162-2166